Palisade Bio

Palisade Bio Diluted EPS

The Diluted Earnings per Share of Palisade Bio (PALI) as of Nov 19, 2026 is -0.30 USD. In the previous year, Diluted Earnings per Share was -1.69 USD — a change of -82.17% (higher).

Diluted EPS

-0.30USD

YoY

-82.17%

Last updated:

Diluted Earnings per Share of Palisade Bio is 2025 -0.30 USD. Diluted Earnings per Share of Palisade Bio was 2024 -1.69 USD. It decreases by -82.17% higher compared to the previous year.

The Palisade Bio Diluted EPS history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Diluted EPS
Date
Diluted EPS
Jan 1, 2018
-18.03 USD
Jan 1, 2019
-35.18 USD
Jan 1, 2020
-43.48 USD
Jan 1, 2021
-98.32 USD
Jan 1, 2022
-7.91 USD
Jan 1, 2023
-1.33 USD
Jan 1, 2024
-1.69 USD
Jan 1, 2025
-0.30 USD
The Palisade Bio Diluted EPS history
YEARDiluted EPSYoY
-0.30USD-82.17%
-1.69USD+27.39%
-1.33USD-83.22%
-7.91USD-91.96%
-98.32USD+126.14%
-43.48USD+23.59%
-35.18USD+95.16%
-18.03USD-75.56%
-73.76USD-41.52%
-126.12USD-35.93%
-196.84USD-9.97%
-218.64USD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Palisade Bio Stock analysis

What does Palisade Bio do? Palisade Bio, Inc. develops oral therapies for gastrointestinal complications caused by post-operative digestive enzyme damage. The company focuses on LB1148, an oral liquid formulation containing tranexamic acid (TXA), polyethylene glycol, carbohydrates, and electrolytes, designed to prevent enzyme leakage into the peritoneal cavity during high-risk surgeries. LB1148 is administered before surgeries to protect the intestinal epithelial barrier. The company's lead product targets acute and chronic conditions resulting from digestive enzyme damage, with no other products or revenue streams mentioned. Palisade Bio, Inc. is a biopharmaceutical company headquartered in Carlsbad, California, employing 12 full-time employees. It went public via IPO on December 20, 2006, but does not generate revenue from product sales as it is in the development phase. The company's business model relies on developing therapies like LB1148 for surgical patients, with no indication of partnerships, licensing deals, or other revenue sources beyond potential future product sales after regulatory approval. The lead therapeutic candidate LB1148 is formulated as an aqueous solution for oral (enteral) administration. The company's approach is based on the discovery that intestinal epithelial barrier damage leads to digestive enzyme leakage, causing tissue damage and inflammation. No other products, brands, or revenue streams are referenced in the business description, and the company does not sell any products at this stage. Palisade Bio is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Palisade Bio stock

Diluted Earnings per Share of Palisade Bio is -0.30 USD in 2025.

Diluted Earnings per Share of Palisade Bio changed from -1.69 USD to -0.30 USD, representing a -82.17% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Diluted Earnings per Share Palisade Bio since 2006 – with annual values, charts, and detailed analysis.

Diluted EPS accounts for all potential shares from options, warrants, and convertible securities. It provides a more conservative per-share earnings measure.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Income Statement — Palisade Bio

All Key Metrics — Palisade Bio